Mufg Securities Americas Inc. Makes New Investment in Kenvue Inc. (NYSE:KVUE)

Mufg Securities Americas Inc. bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the fourth quarter, Holdings Channel.com reports. The firm bought 28,302 shares of the company’s stock, valued at approximately $604,000.

Several other institutional investors have also recently made changes to their positions in KVUE. Handelsbanken Fonder AB grew its stake in Kenvue by 2.9% in the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock worth $15,846,000 after purchasing an additional 21,222 shares during the period. Alberta Investment Management Corp grew its position in shares of Kenvue by 23.2% in the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock worth $12,445,000 after buying an additional 109,700 shares during the period. Longbow Finance SA increased its stake in shares of Kenvue by 5.0% in the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company’s stock worth $5,990,000 after acquiring an additional 13,287 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its position in Kenvue by 143.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company’s stock valued at $1,023,000 after acquiring an additional 28,216 shares during the period. Finally, CORDA Investment Management LLC. lifted its position in Kenvue by 1.4% during the 4th quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company’s stock valued at $26,754,000 after acquiring an additional 17,466 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE stock opened at $23.86 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $25.17. The company has a market cap of $45.78 billion, a P/E ratio of 45.02, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The stock’s fifty day moving average price is $23.15 and its 200-day moving average price is $22.58.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Kenvue’s revenue was down 3.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.28 earnings per share. On average, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.44%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on KVUE. Evercore ISI assumed coverage on shares of Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective on the stock. Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Barclays lifted their price objective on Kenvue from $22.00 to $23.00 and gave the company an “equal weight” rating in a research note on Monday. Finally, Citigroup increased their target price on Kenvue from $22.00 to $24.50 and gave the stock a “neutral” rating in a research note on Friday, May 9th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.